---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-006560"
form_type: "8-K"
ticker: "NDRA"
cik: "0001681682"
company_name: "ENDRA Life Sciences Inc."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T01:17:49.844843+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ENDRA Life Sciences Q1 net loss $2.9M ($0.93/share); cash $2.4M; raised $4.5M in public offering

## Summary
- Net loss $2.9M ($0.93 per share) in Q1 2023, flat vs $2.9M ($1.33 per share) in Q1 2022.
- Operating expenses $2.9M unchanged YoY; cash and equivalents $2.4M at March 31, 2023.
- Completed data collection for FDA De Novo submission for TAEUS liver fat device; submission planned mid-2023.
- Raised $4.5M net proceeds from public offering subsequent to quarter-end, extending cash runway.
- Added 7 patents year-to-date (3 US, 2 Europe, 2 China); IP portfolio now 63 issued patents.

## SEC filing metadata
- accession: 0001654954-23-006560
- form_type: 8-K
- ticker: NDRA
- cik: 0001681682
- company_name: ENDRA Life Sciences Inc.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681682/000165495423006560/0001654954-23-006560-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681682/000165495423006560/ndra_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-006560
- JSON: https://secwatch.observer/filing/0001654954-23-006560.json
- Plain text: https://secwatch.observer/filing/0001654954-23-006560.txt

## Key facts
- Earnings Releases
  ENDRA Life Sciences Inc. reported the three months ended March 31, 2023 results: net income $2.9 million, EPS $0.93 per share.
  - Period: the three months ended March 31, 2023
  - Net income: $2.9 million
  - EPS: $0.93 per share
  - Result: reported results
  source text: First Quarter 2023 Financial Results In the first quarter of 2023, our operating expenses were $2.9 million, unchanged from the first quarter in 2022. Increases in research and development and general and administrative expenses were offset by decreases in sales and marketing expenses. Net loss in the first quarter of 2023 was $2.9 million, or $0.93 per share, compared with a net loss of $2.9 million, or $1.33 per share, in the first quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1681682/000165495423006560/0001654954-23-006560-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.